Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During their preparation for this battle, B cells transiently revert to a more ...

On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...

This story is part 3 in a four-part series about cell therapy created by the Fierce Biotech team. Part 1 is available here, part 2 is here and the final installment is here. Gabrielle Masson, Helen ...

Johns Hopkins Medicine scientists say they have developed a simplified version of biodegradable nanoparticles that can "educate" the immune system to find and destroy disease-causing cells throughout ...

Researchers headed by a team at Seattle Children’s Research Institute have shown for the first time that engineered human plasma B cells can be used to treat a disease—more specifically leukemia—in a ...

B-PLL is a rare subtype that’s more aggressive than other blood cancers and has a low survival rate. However, ongoing research and clinical trials may offer new treatment options to improve outcomes.